Bessemer Group’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.93M | Buy |
24,080
+5,444
| +29% | +$449K | ﹤0.01% | 820 |
|
|
2025
Q4 | $1.59M | Sell |
18,636
-279
| -1% | -$22.9K | ﹤0.01% | 857 |
|
|
2025
Q3 | $1.47M | Buy |
18,915
+2,819
| +18% | +$220K | ﹤0.01% | 561 |
|
|
2025
Q2 | $1.26M | Sell |
16,096
-1,005
| -6% | -$75K | ﹤0.01% | 575 |
|
|
2025
Q1 | $1.24M | Sell |
17,101
-15,654
| -48% | -$1.12M | ﹤0.01% | 616 |
|
|
2024
Q4 | $2.42M | Sell |
32,755
-362,795
| -92% | -$25.4M | ﹤0.01% | 609 |
|
|
2024
Q3 | $26.1M | Buy |
395,550
+3,418
| +0.9% | +$248K | 0.04% | 221 |
|
|
2024
Q2 | $36.2M | Sell |
392,132
-982
| -0.2% | -$87K | 0.06% | 200 |
|
|
2024
Q1 | $37.6M | Sell |
393,114
-39,624
| -9% | -$3.33M | 0.07% | 205 |
|
|
2023
Q4 | $33M | Sell |
432,738
-3,089
| -0.7% | -$215K | 0.06% | 207 |
|
|
2023
Q3 | $30.2M | Buy |
435,827
+17,719
| +4% | +$1.42M | 0.07% | 204 |
|
|
2023
Q2 | $39.4M | Sell |
418,108
-213,635
| -34% | -$18.6M | 0.08% | 198 |
|
|
2023
Q1 | $52.3M | Sell |
631,743
-60,569
| -9% | -$4.76M | 0.12% | 179 |
|
|
2022
Q4 | $51.7M | Sell |
692,312
-166,732
| -19% | -$12.9M | 0.13% | 172 |
|
|
2022
Q3 | $71M | Sell |
859,044
-29,154
| -3% | -$2.81M | 0.19% | 144 |
|
|
2022
Q2 | $84.5M | Sell |
888,198
-186,260
| -17% | -$19.3M | 0.21% | 139 |
|
|
2022
Q1 | $126M | Sell |
1,074,458
-101,388
| -9% | -$11.4M | 0.27% | 118 |
|
|
2021
Q4 | $152M | Buy |
1,175,846
+8,084
| +0.7% | +$943K | 0.31% | 106 |
|
|
2021
Q3 | $132M | Buy |
1,167,762
+326
| +0% | +$37.2K | 0.28% | 121 |
|
|
2021
Q2 | $121M | Buy |
1,167,436
+105,947
| +10% | +$9.99M | 0.26% | 127 |
|
|
2021
Q1 | $88.8M | Buy |
1,061,489
+209,381
| +25% | +$17.7M | 0.21% | 142 |
|
|
2020
Q4 | $77.7M | Sell |
852,108
-1,004
| -0.1% | -$83.3K | 0.2% | 136 |
|
|
2020
Q3 | $68.1M | Buy |
853,112
+140,177
| +20% | +$10.9M | 0.2% | 126 |
|
|
2020
Q2 | $49.3M | Sell |
712,935
-39,927
| -5% | -$2.84M | 0.16% | 139 |
|
|
2020
Q1 | $47.3M | Sell |
752,862
-177,963
| -19% | -$12.8M | 0.19% | 131 |
|
|
2019
Q4 | $72.4M | Sell |
930,825
-489,240
| -34% | -$38.2M | 0.23% | 122 |
|
|
2019
Q3 | $104M | Sell |
1,420,065
-90,891
| -6% | -$6.38M | 0.37% | 78 |
|
|
2019
Q2 | $93M | Buy |
1,510,956
+1,508,277
| +56,300% | +$91.2M | 0.31% | 98 |
|
|
2019
Q1 | $172K | Buy |
2,679
+1,401
| +110% | +$80K | ﹤0.01% | 1014 |
|
|
2018
Q4 | $65K | Buy |
1,278
+417
| +48% | +$21.1K | ﹤0.01% | 1254 |
|
|
2018
Q3 | $50K | Buy |
861
+810
| +1,588% | +$39.6K | ﹤0.01% | 1266 |
|
|
2018
Q2 | $2K | Hold |
51
| – | – | ﹤0.01% | 1619 |
|
|
2018
Q1 | $2K | Buy |
+51
| New | +$2.21K | ﹤0.01% | 1598 |
|
|
2017
Q4 | – | Sell |
-120
| Closed | -$4K | – | 1722 |
|
|
2017
Q3 | $4K | Buy |
+120
| New | +$4.58K | ﹤0.01% | 1681 |
|
|
2017
Q1 | – | Sell |
-138
| Closed | -$4K | – | 1793 |
|
|
2016
Q4 | $4K | Buy |
+138
| New | +$4.47K | ﹤0.01% | 1777 |
|
|
2016
Q3 | – | Sell |
-749,052
| Closed | -$24.9M | – | 1819 |
|
|
2016
Q2 | $24.9M | Buy |
749,052
+257,196
| +52% | +$8.8M | 0.14% | 145 |
|
|
2016
Q1 | $14.5M | Buy |
+491,856
| New | +$13.6M | 0.08% | 162 |
|
|
2015
Q4 | – | Sell |
-252
| Closed | -$6K | – | 1609 |
|
|
2015
Q3 | $6K | Sell |
252
-84,948
| -100% | -$2.05M | ﹤0.01% | 1292 |
|
|
2015
Q2 | $2.02M | Hold |
85,200
| – | – | 0.01% | 416 |
|
|
2015
Q1 | $2.02M | Buy |
85,200
+15,990
| +23% | +$359K | 0.01% | 409 |
|
|
2014
Q4 | $1.47M | Buy |
+69,210
| New | +$1.39M | 0.01% | 426 |
|
|
2013
Q3 | – | Sell |
-234
| Closed | -$3K | – | 1273 |
|
|
2013
Q2 | $3K | Buy |
+234
| New | +$2.77K | ﹤0.01% | 1211 |
|
Other funds holding EW
VCM
VPM
Bessemer Group's EW Position: Q1 2026 in Review
Bessemer Group increased its Edwards Lifesciences (EW) stake by 29% in Q1 2026, buying an estimated $449K and bringing the position to 24,080 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #820.
Bessemer Group first reported a position in EW in Q2 2013 and has held it in 42 quarters since. The position peaked at $152M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Bessemer Group held 24,080 shares of Edwards Lifesciences worth $1.93M as of Q1 2026.
- Bessemer Group bought 5,444 Edwards Lifesciences shares in Q1 2026, an estimated $449K.
- Edwards Lifesciences made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #820 holding.
- Bessemer Group first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 42 quarters since.
- Bessemer Group's Edwards Lifesciences position peaked at $152M in Q4 2021.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.